David J. Vining

David J. Vining is a Professor at The University of Texas MD Anderson Cancer Center. His research focuses on oncology, cancer immunotherapy, and molecular cancer therapeutics, with particular emphasis on therapeutic targets, pharmacotherapy, and radiation oncology. His latest work includes clinical outcomes of patients with TP53 and DNA repair pathway alterations from the MD Anderson IMPACT 2 study (2026, *Journal of Clinical Oncology*), atypical radiologic response patterns in immunotherapy trials (2026, *Journal of Clinical Oncology*), and a Phase I trial of TTI-101, a first-in-class oral STAT3 inhibitor, in advanced solid tumors (2025, *Clinical Cancer Research*). He also investigates autologous tumor-infiltrating lymphocytes in recurrent ovarian, colorectal, and pancreatic cancers (2024, *Journal for ImmunoTherapy of Cancer*). His research integrates precision oncology and molecular profiling to advance targeted cancer treatment strategies.